Originalarbeiten
Veselinović T, Vernaleken I, Janouschek H, Cumming P, Paulzen M, Mottaghy FM, Gründer G. The role of striatal dopamine D2/3 receptors in cognitive performance in drug-free patients with schizophrenia. Psychopharmacology (Berl) 2018; 235(8): 2221-2232.
Veselinović T, Vernaleken I, Cumming P, Henning U, Winkler L, Kaleta P, Paulzen M, Luckhaus C, Gründer G. Antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion. Neuropsychiatr Dis Treat. 2018; 14: 1125-1138.
Klasen M, Wolf D, Eisner PD, Habel U, Repple J, Vernaleken I, Schlüter T, Eggermann T, Zerres K, Zepf FD, Mathiak K. Neural networks underlying trait aggression depend on MAOA gene alleles. Brain Struct Funct 2018; 223(2):873-881.
Pfeifer P, Tüscher O, Buchholz HG, Gründer G, Vernaleken I, Paulzen M, Zimmermann US, Maus S, Lieb K, Eggermann T, Fehr C, Schreckenberger M. Acute effect of intravenously applied alcohol in the human striatal and extrastriatal D2 /D3 dopamine system. Addict Biol 2017; 22(5): 1449-1458.
Schlüter T, Schliwa ES, May VD, Lammertz SE, Vernaleken I. A competitively designed version of the point subtraction aggression paradigm is related to proactive aggressive and psychopathic traits in males. Psychiatry Res 2017; 256: 318-327.
Rademacher L, Prinz S, Winz O, Henkel K, Dietrich CA, Schmaljohann J, Mohammadkhani Shali S, Schabram I, Stoppe C, Cumming P, Hilgers RD, Kumakura Y, Coburn M, Mottaghy FM, Gründer G, Vernaleken I. Effects of Smoking Cessation on Presynaptic Dopamine Function of Addicted Male Smokers. Biol Psychiatry 2016; 80(3):198-206.
Schlüter T, Winz O, Henkel K, Eggermann T, Mohammadkhani-Shali S, Dietrich C, Heinzel A, Decker M, Cumming P, Zerres K, Piel M, Mottaghy FM, Vernaleken I. MAOA-VNTR Polymorphism Modulates Context-dependent Dopamine Release and Aggressive Behavior in Males. Neuroimage 2016; 125: 378-85. 5.463 x
Pfeifer P, Sariyar M, Eggermann T, Zerres K, Vernaleken I, Tüscher O, Fehr C. Alcohol Consumption in Healthy OPRM1 G Allele Carriers and Its Association with Impulsive Behavior. Alcohol Alcohol 2015; 50(4): 379-84.
Rong Y, Vernaleken I, Winz OH, Goedicke A, Mottaghy FM, Kops ER. Simulation-based partial volume correction for dopaminergic PET imaging: Impact of segmentation accuracy. Z Med Phys 2015; 25(3): 230-42.
Veselinovic T, Vernaleken I, Janouschek H, Kellermann T, Paulzen M, Cumming P, Gründer G. Effects of anticholinergic challenge on psychopathology and cognition in drug-free patients with schizophrenia and healthy volunteers. Psychopharmacology (Berl) 2015; 232(9): 1607-17.
► frühere Originalarbeiten
Pelzer B, Schaffrath S, Vernaleken I. Coping with unemployment: The impact of unemployment on mental health, personality, and social interaction Work 2014; 48(2): 289-95.
Piel M, Vernaleken I, Rösch F. Positron Emission Tomography in CNS Drug Discovery and Drug Monitoring. J Med Chem 2014; 57(22): 9232-58.
Prinz S, Gründer G, Hilgers RD, Holtemöller O, Vernaleken I. Impact of personal economic environment and personality factors on individual financial decision making. Front Psychol 2014; 5: 158.
Schabram I, Henkel K, Shali SM, Dietrich C, Schmaljohann J, Winz O, Prinz S, Rademacher L, Neumaier B, Felzen M, Kumakura Y, Cumming P, Mottaghy FM, Gründer G, Vernaleken I. Acute and Sustained Effects of Methylphenidate on Cognition and Presynaptic Dopamine Metabolism: An [18F]FDOPA PET Study. J Neurosci 2014; 34(44): 14769-76.
Cumming P, Xiong G, Fougère CL, Rominger A, Bartenstein P, Buchholz HG, Piel M, Rösch F, Gründer G, Vernaleken I. Surrogate markers for cerebral blood flow correlate with [(18) F]-fallypride binding potential at dopamine D(2/3) receptors in human striatum. Synapse 2013; 67(4): 199-203.
Kumakura Y, Gjedde A, Caprioli D, Kienast T, Beck A, Plotkin M, Schlagenhauf F, Vernaleken I, Gründer G, Bartenstein P, Heinz A, Cumming P. Increased turnover of dopamine in caudate nucleus of detoxified alcoholic patients. PLoS One 2013; 8(9): e73903.
Schabram I, Eggermann T, Siegel SJ, Gründer G, Zerres K, Vernaleken I. Neuropsychological correlates of transcription factor AP-2Beta, and its interaction with COMT and MAOA in healthy females. Neuropsychobiology 2013; 68(2): 79-90.
Schlüter T, Winz O, Henkel K, Prinz S, Rademacher L, Schmaljohann J, Dautzenberg K, Cumming P, Kumakura Y, Rex S, Mottaghy FM, Gründer G, Vernaleken I. The Impact of Dopamine on Aggression: An [18F]-FDOPA PET Study in Healthy Males. J Neurosci 2013; 33(43): 16889-96.
Vernaleken I, Klomp M, Moeller O, Raptis M, Nagels A, Rösch F, Schaefer WM, Cumming P, Gründer G. Vulnerability to psychotogenic effects of ketamine is associated with elevated D2/3-receptor availability. Int J Neuropsychopharmacol 2013; 16(4): 745-54.
Veselinovic T, Schorn H, Vernaleken IB, Hiemke C, Zernig G, Gur R, Gründer G. Effects of antipsychotic treatment on cognition in healthy subjects. J Psychopharmacol 2013; 27(4): 374-385.
Kuhn J, Janouschek H, Raptis M, Rex S, Lenartz D, Neuner I, Mottaghy FM, Schneider F, Schaefer WM, Sturm V, Gründer G, Vernaleken I. In Vivo Evidence of Deep Brain Stimulation-Induced Dopaminergic Modulation in Tourette's Syndrome. Biol Psychiatry. 2012;71(5):e11-3.
Vernaleken I, Peters L, Raptis M, Lin R, Buchholz HG, Zhou Y, Winz O, Rösch F, Bartenstein P, Wong DF, Schäfer WM, Gründer G. The applicability of SRTM in [(18)F]fallypride PET investigations: impact of scan durations. J Cerebr Blood F Met 2011; 31: 1958-66.
Gründer G, Hiemke C, Paulzen M, Veselinovic T, Vernaleken I. Therapeutic Plasma Concentrations of Antidepressants and Antipsychotics: Lessons from PET Imaging. Pharmacopsychiatry 2011; 44: 236-48.
Spreckelmeyer KN, Paulzen M, Raptis M, Baltus T, Schaffrath S, Van Waesberghe J, Zalewski MM, Rösch F, Vernaleken I, Schäfer WM, Gründer G. Opiate-induced dopamine release is modulated by severity of alcohol dependence: an [(18)f]fallypride positron emission tomography study. Biol Psychiat 2011; 70: 770-6.
Veselinovic T, Schorn H, Vernaleken I, Schiffl K, Hiemke C, Zernig G, Gur R, Gründer G. Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers. Psychopharmacology (Berl). 2011 Dec;218(4):733-48.
Veselinovic T, Schorn H, Vernaleken IB, Schiffl K, Klomp M, Gründer G. Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion. J Clin Psychopharm 2011; 31: 214-20.
Bernow N, Yakushev I, Landvogt C, Buchholz HG, Smolka MN, Bartenstein P, Lieb K, Gründer G, Vernaleken I, Schreckenberger M, Fehr C. Dopamine D2/D3 receptor availability and venturesomeness. Psychiat Res 2011; 193: 80-84.
Habel U, Vernaleken I. Imaging bei Schizophrenien und Psychosen. Besseres Krankheitsverständnis durch Bildgebung. Neurotraansmitter 2010. Sonderheft 2: 8-22.
Vernaleken I, Janouschek H, Raptis M, Hellmann S, Veselinovic T, Bröcheler A, Boy C, Cumming P, Hiemke C, Rösch F, Schäfer WM, Gründer G. Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas. Int J Neuropsychopharmacol 2010; 13(7): 951-60.
Gründer G, Vernaleken I, Bartenstein P. Anwendungen von PET und SPECT in der Psychiatrie. [Use of PET and SPECT in psychiatry.] Nervenarzt 2010;81(1): 97-107; quiz 108.
Kumakura Y, Danielsen EH, Gjedde A, Vernaleken I, Buchholz HG, Heinz A, Gründer G, Bartenstein P, Cumming P. Elevated [(18)F]FDOPA utilization in the periaqueductal gray and medial nucleus accumbens of patients with early Parkinson's disease. Neuroimage 2010; 49: 2933-2939.
Kumakura Y, Vernaleken I, Buchholz HG, Borghammer P, Danielsen E, Gründer G, Heinz A, Bartenstein P, Cumming P. Age-dependent decline of steady state dopamine storage capacity of human brain: an FDOPA PET study. Neurobiol Aging 2010; 31(3): 447-63.
Vernaleken I, Kuhn J, Lenartz D, Raptis M, Huff W, Janouschek H, Neuner I, Schaefer WM, Gründer G, Sturm V. Bithalamical deep brain stimulation in tourette syndrome is associated with reduction in dopaminergic transmission. Biol Psychiatry 2009; 66(10): e15-17.
Kawohl W, Schneider F, Vernaleken I, Neuner I. Chronic motor tic disorder and aripiprazole. J Neuropsychiatry Clin Neurosci 2009; 21:224.
Vernaleken I, Fellows C, Janouschek H, Bröcheler A, Veselinovic T, Landvogt C, Boy C, Buchholz HG, Spreckelmeyer K, Bartenstein P, Cumming P, Hiemke C, Rösch F, Schäfer W, Wong DF, Gründer G. Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). J Clin Psychopharmacol 2008; 28(6): 608-617.
Gründer G, Fellows C, Janouschek H, Veselinovic T, Boy C, Bröcheler A, Kirschbaum KM, Hellmann S, Spreckelmeyer KM, Hiemke C, Rösch F, Schaefer WM, Vernaleken I. Brain and plasma pharmacokinetics of Aripiprazole in patients with schizophrenia: an [18F]fallypride PET study.Am J Psychiatry 2008; 165: 988-995.
Vernaleken I, Kumakura Y, Buchholz HG, Siessmeier T, Hilgers RD, Bartenstein P, Cumming P, Gründer G. Baseline [18F]-FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: A positron emission tomography study in healthy subjects. Neuroimage 2008; 40: 1222-1231.
Kumakura Y, Cumming P, Vernaleken I, Buchholz HG, Siessmeier T, Heinz A, Kienast T, Bartenstein P, Gründer G. Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/positron emission tomography study. J Neurosci 2007; 27: 8080-8087.
Vernaleken I, Weibrich C, Siessmeier T, Buchholz HG, Rosch F, Heinz A, Cumming P, Stoeter P, Bartenstein P, Gründer G. Asymmetry in dopamine D(2/3) receptors of caudate nucleus is lost with age. Neuroimage 2007; 34: 870-878.
Vernaleken I, Buchholz HG, Kumakura Y, Siessmeier T, Stoeter P, Bartenstein P, Cumming P, Gründer G. 'Prefrontal' cognitive performance of healthy subjects positively correlates with cerebral FDOPA influx: An exploratory [(18)F]-fluoro-L-DOPA-PET investigation. Hum Brain Mapp 2007; 28: 931-939.
Vernaleken I, Kumakura Y, Cumming P, Buchholz HG, Siessmeier T, Stoeter P, Müller MJ, Bartenstein P, Gründer G. Modulation of [(18)F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge. Neuroimage 2006; 30: 1332-1339.
Gründer G, Landvogt C, Vernaleken I, Buchholz HG, Ondracek J, Siessmeier T, Hartter S, Schreckenberger M, Stoeter P, Hiemke C, Rosch F, Wong DF, Bartenstein P. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology 2006; 31: 1027-1035.
Kumakura Y, Vernaleken I, Gründer G, Bartenstein P, Gjedde A, Cumming P. PET studies of net blood-brain clearance of FDOPA to human brain: age-dependent decline of [18F]fluorodopamine storage capacity. Journal of Cerebral Blood Flow and Metabolism 2005; 25: 807-819.
Siessmeier T, Zhou Y, Buchholz H-G, Landvogt C, Vernaleken I, Piel M, Schirrmacher R, Rösch F, Schreckenberger M, Wong DF, Cumming P, Gründer G, Bartenstein P. Parametric Mapping of the Binding in Human Brain of D2-Receptor Ligands of Different Affinities. Journal of Nuclear Medicine 2005; 6: 964-972.
Vernaleken I, Siessmeier T, Buchholz H-G, Härtter S, Hiemke C, Stoeter P, Rösch F, Bartenstein P, Gründer G. High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. International Journal of Neuropsychopharmacology 2004; 7: 421-430.
Hiemke C, Dragicevic A, Gründer G, Härtter S, Sachse J, Vernaleken I, Müller MJ. Therapeutic monitoring of new antipsychotic drugs. Therapeutic Drug Monitoring 2004; 26:156-160.
Gründer G, Siessmeier T, Piel M, Vernaleken I, Buchholz H-G, Zhou Y, Hiemke C, Wong DF, Rösch F, Bartenstein P. Quantification of D2-like dopamine receptors in the human brain with [18F]desmethoxyfallypride. Journal of Nuclear Medicine 2003; 44: 109-116.
Gründer G, Vernaleken I, Müller MJ, Davids E, Heydari N, Buchholz H-G, Bartenstein P, Munk O, Stoeter P, Wong DF, Gjedde A, Cumming P. Subchronic haloperidol downregulates dopamine synthesis capacity in brain of schizophrenic patients in vivo. Neuropsychopharmacology 2003; 28: 787-794.
Müller MJ, Sachse J, Vernaleken I, Gründer G, Härtter S, Hiemke C. Therapeutisches Drug-Monitoring von Amisulprid in der klinischen Routine. Psychopharmakotherapie 2003; 20: 23-27.
Gründer G, Vernaleken I, Benkert O. Welche Eigenschaften machen ein Neuroleptikum "atypisch"? Der Nervenarzt 2001; 72: 833-843.
Gründer G, Siessmeier T, Lange-Asschenfeldt C, Vernaleken I, Buchholz H-G, Stoeter P, Drzezga A, Lüddens H, Rösch F, Bartenstein P. PET imaging of benzodiazepine receptors in the human brain with [18F]fluoroethylflumazenil. European Journal of Nuclear Medicine 2001; 28: 1463-1470.
Krämer, T, Vernaleken I, Maurer HH. Studies on the metabolism and toxicological detection of the amphetamine-like anorectic mefenorex in human urine by gas chromatography-mass spectrometry and fluorescence polarization immunoassay. J Chromatogr B Biomed Sci Appl. 1997; 702: 93-102.
Weitere Informationen zu den wissenschaftlichen Veröffentlichungen entnehmen Sie bitte der Literatur-Datenbank PubMed.
